Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:ISO

IsoPlexis (ISO) Stock Price, News & Analysis

IsoPlexis logo

About IsoPlexis Stock (NASDAQ:ISO)

Advanced Chart

Key Stats

Today's Range
$0.76
$0.76
50-Day Range
$0.74
$1.13
52-Week Range
$0.60
$5.10
Volume
N/A
Average Volume
68,375 shs
Market Capitalization
$30.28 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

IsoPlexis Corporation, a life sciences company, provides solutions for the development of curative medicines and personalized therapeutics in the United States, Canada, the United Kingdom, Belgium, France, the Czech Republic, Spain, Germany, Sweden, Italy, Israel, Switzerland, China and Taiwan, Singapore, Japan, Australia, and Korea. The company offers single cell proteomics platform, including instruments, chip consumables, and software that provides an end-to-end solution to view of protein function at an individual cellular level. It provides IsoLight and IsoSpark instruments; IsoCode chips that offer multiplexed chip solutions for single cell functional proteomics; CodePlex chips that provide multiplexed solutions for ultra-low volume bulk samples; and IsoSpeak software that offers dimensional data and automates analysis with an intuitive push button user interface to deliver same day single cell and bulk proteome visualizations, as well as research support and services, and post-warranty services. The company was incorporated in 2013 and is based in Branford, Connecticut.

Receive ISO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for IsoPlexis and its competitors with MarketBeat's FREE daily newsletter.

ISO Stock News Headlines

Truecaller earns triple ISO certifications
Buffett, Gates and Bezos Quietly Dumping Stocks
In just six months, some of the richest men in the world have liquidated billions in blue-chip stocks. Jim Rickards says they aren’t just cashing out—they’re reallocating into a specific corner of the market poised to benefit from new federal policy. He’s now revealing what everyday investors can do to prepare.
See More Headlines

ISO Stock Analysis - Frequently Asked Questions

IsoPlexis Co. (NASDAQ:ISO) posted its quarterly earnings results on Wednesday, November, 10th. The company reported ($10.66) earnings per share for the quarter, missing analysts' consensus estimates of ($0.79) by $9.87. The company earned $4.19 million during the quarter, compared to the consensus estimate of $3.79 million. IsoPlexis had a negative net margin of 632.41% and a negative trailing twelve-month return on equity of 127.86%.

IsoPlexis (ISO) raised $125 million in an IPO on Friday, October 8th 2021. The company issued 8,333,000 shares at $14.00-$16.00 per share.

Based on aggregate information from My MarketBeat watchlists, some other companies that IsoPlexis investors own include Biora Therapeutics (BIOR), NIO (NIO), PayPal (PYPL), Alibaba Group (BABA), Robinhood Markets (HOOD) and Lucid Group (LCID).

Company Calendar

Last Earnings
11/10/2021
Today
5/18/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Analytical instruments
Sub-Industry
N/A
Current Symbol
NASDAQ:ISO
Fax
N/A
Employees
459
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-106,000,000.00
Net Margins
-632.41%
Pretax Margin
-632.40%

Debt

Sales & Book Value

Annual Sales
$16.76 million
Price / Cash Flow
N/A
Book Value
$1.04 per share
Price / Book
0.73

Miscellaneous

Free Float
37,218,000
Market Cap
$30.28 million
Optionable
Not Optionable
Beta
1.32
7 Energy Stocks to Buy and Hold Forever Cover

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

This page (NASDAQ:ISO) was last updated on 5/18/2025 by MarketBeat.com Staff
From Our Partners